VEEV
Veeva Systems Inc.
Healthcare · Health Information Services · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- Veeva's profitability sub-score of 18.8 out of 20 and growth sub-score of 17.5 out of 20 are both near-maximum, anchoring the score firmly above average and reflecting genuinely strong operating fundamentals documented in the FY2026 10-K.
- The momentum sub-score of 14.0 out of 20 adds further support by confirming that quarterly operational metrics are improving sequentially, not just on an annual basis.
- Despite strong operating metrics, the financial health sub-score of 8.0 and the two zero-weighted categories (dividend and theme) suppress the aggregate to 53.9, placing it in a middle tier rather than among the highest-scoring research candidates.
Why Not Higher
- The zero scores in both dividend (0.0) and theme (0.0) sub-categories mean that 40 potential model points are entirely unearned, and without dividend income characteristics or identifiable macro theme exposure, the model has no mechanism to push the score significantly higher.
- The financial health sub-score of 8.0 is a meaningful drag relative to the otherwise strong operating profile, and if leverage, coverage ratios, or balance sheet metrics do not improve, this constraint will continue to limit the composite score.
Data Confidence
6 / 10
Medium — some data gaps
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Veeva Systems Inc. is a cloud computing company specializing in industry-specific software solutions for the global life sciences industry, including pharmaceutical, biotechnology, and medical device companies. Its platform spans clinical data management, regulatory affairs, quality management, commercial operations, and medical affairs, making it a deeply embedded technology partner across the drug development and commercialization lifecycle. The company transitioned from a public benefit corporation structure to a Delaware corporation, and its FY2026 10-K filings reflect a business that continues to generate strong profitability and consistent revenue growth within its specialized niche. The model scored Veeva 53.9/100, reflecting genuinely strong profitability and growth sub-scores — 18.8 and 17.5 respectively out of 20 — that confirm healthy margins and meaningful year-over-year expansion in revenue and earnings. However, the financial health sub-score of 8.0 introduces caution, suggesting leverage or balance sheet characteristics that constrain the overall score, while the dividend and theme sub-scores both register 0.0, reflecting an absence of dividend income and no mapped macro theme exposure in the current model version. The core research tradeoff here is between a highly profitable, niche-dominant software business with clear growth momentum and the limitations imposed by incomplete metric mapping, a subdued financial health reading, and the zero-weighted qualitative categories that suppress the aggregate score below what the profitability and growth profile alone might otherwise suggest.
Plain English
Veeva Systems builds specialized software that pharmaceutical and biotech companies use to run their clinical trials, manage regulatory filings, and handle sales operations — it is deeply embedded in an industry that cannot easily switch vendors. The model score of 53.9 out of 100 reflects strong profitability and solid growth, but is pulled down by financial health concerns and two sub-scores that contribute nothing to the total. The High risk rating means the model sees meaningful uncertainty in the overall picture — not necessarily that the business is fragile, but that an aggressive-growth profile like this carries real downside if growth decelerates or balance sheet pressures emerge.
Bull Case vs. Bear Case
Bull Case
- The profitability sub-score of 18.8 out of 20 indicates exceptionally strong net and operating margins, consistent with a high-retention SaaS business model serving customers with limited switching alternatives.
- The growth sub-score of 17.5 out of 20 reflects robust year-over-year revenue, net income, and EPS expansion as documented in the FY2026 10-K, suggesting Veeva continues to penetrate its addressable market across clinical, commercial, and quality product suites.
- The momentum sub-score of 14.0 out of 20 points to meaningful sequential improvement in quarterly revenue and earnings, indicating the business is not merely holding steady but is accelerating on a filing-derived basis.
Bear Case
- The financial health sub-score of 8.0 out of 20 is the weakest non-zero reading in the profile and raises questions about leverage ratios, interest coverage, or balance sheet composition that could become a constraint if macro credit conditions tighten.
- Both the dividend sub-score (0.0) and theme sub-score (0.0) contribute nothing to the aggregate model score, meaning two full scoring categories are structurally absent, which caps the ceiling of this research candidate relative to higher-scoring peers.
- Only 6 of 10 core metrics were successfully mapped from the EDGAR filing, reducing model confidence to 6.0 out of 10 and leaving meaningful analytical gaps that could be hiding either risks or strengths not yet captured.
What Could Change the Picture
Bullish Triggers
- A material improvement in the financial health sub-score — driven by reduced leverage, stronger interest coverage ratios, or a cleaner balance sheet as documented in a future 10-K — would directly lift the composite model score and reduce the High risk rating.
- Successful mapping of the remaining 4 of 10 core metrics, combined with an improvement in model confidence above 7.0 out of 10, would reduce analytical uncertainty and potentially reveal additional scoring upside currently obscured by data gaps.
Bearish Triggers
- A deceleration in the growth sub-score below 14.0, driven by slowing year-over-year revenue or EPS growth in a future 10-K filing, would undermine the primary bullish thesis and could push the composite score toward the low 40s range.
- Any further deterioration in the financial health sub-score below 8.0 — signaling worsening leverage or declining interest coverage — would reinforce the bear case and potentially elevate the risk rating beyond its current High designation.
Red Flags
- The financial health sub-score of 8.0 is materially below the profitability and growth readings, suggesting a potential imbalance between operating performance and balance sheet structure that warrants closer examination of the FY2026 10-K leverage and liquidity disclosures.
- With only 6 of 10 core metrics mapped and a confidence score of 6.0 out of 10, the model's coverage of Veeva's financials is incomplete, meaning the composite score of 53.9 carries higher-than-typical uncertainty.
Risk Profile
High RiskThe High risk rating for Veeva Systems reflects a combination of an incomplete metric mapping set, a notably weak financial health sub-score relative to its otherwise strong operating profile, and the zero contributions from dividend and theme categories, all of which create meaningful model uncertainty for a single-sector SaaS business with a concentrated life sciences customer base.
Key Catalysts to Watch
The primary catalysts to monitor are Veeva's continued expansion of its Vault platform into clinical and quality management — which would sustain the high growth and profitability sub-scores — and any disclosed changes to balance sheet leverage or capital allocation strategy in future SEC filings that could shift the financial health sub-score materially in either direction.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.